GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Growth Rank

Biosyent (TSXV:RX) Growth Rank : 10 (As of Mar. 14, 2025)


View and export this data going back to 1979. Start your Free Trial

What is Biosyent Growth Rank?

Biosyent has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Competitive Comparison of Biosyent's Growth Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's Growth Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Growth Rank distribution charts can be found below:

* The bar in red indicates where Biosyent's Growth Rank falls into.



Biosyent Growth Rank Related Terms

Thank you for viewing the detailed overview of Biosyent's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.
Executives
Blair Driscoll 10% Security Holder
Merrilyn Joy Driscoll 10% Security Holder
Sean Driscoll 10% Security Holder
Fax Capital Corp. 10% Security Holder
Fax Investments Inc. 10% Security Holder
Federated Capital Corp. 10% Security Holder
Seyed Ahmad Ashrafi Director
Robert Joseph March Senior Officer
Peter Douglas Lockhard Director
Sharan Raghubir Senior Officer
Rene Goehrum 10% Security Holder, Director, Senior Officer
Biosyent Inc. Issuer
Joost Van Der Mark Senior Officer
Sara Elford Director
Alfred D'souza Director

Biosyent Headlines

No Headlines